LEADER 01941nam  2200565 a 450 
001 9910824260303321
005 20240410171208.0
010   $a1-61668-478-X
035   $a(CKB)2560000000068770
035   $a(EBL)3019875
035   $a(SSID)ssj0000415799
035   $a(PQKBManifestationID)12173982
035   $a(PQKBTitleCode)TC0000415799
035   $a(PQKBWorkID)10416286
035   $a(PQKB)11606005
035   $a(MiAaPQ)EBC3019875
035   $a(Au-PeEL)EBL3019875
035   $a(CaPaEBR)ebr10674883
035   $a(OCoLC)923662021
035   $a(EXLCZ)992560000000068770
100   $a20100122d2010      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aDevelopment of new MDR-tuberculosis drugs$b[electronic resource] /$fJarmila Vins?ova? and Martin Kra?tky?
205   $a1st ed.
210   $aNew York $cNova Science Publishers/Nova Biomedical$dc2010
215   $a1 online resource (112 p.)
225 1 $aPharmacology-research, safety testing and regulation
300   $aDescription based upon print version of record.
311   $a1-61668-233-7 
320   $aIncludes bibliographical references and index.
327   $aResistance to commonly used drugs, mechanism of the action -- Research of novel MDR potential drugs.
410  0$aPharmacology-research, safety testing, and regulation series.
606   $aAntitubercular agents
606   $aMultidrug-resistant tuberculosis$xChemotherapy
615  0$aAntitubercular agents.
615  0$aMultidrug-resistant tuberculosis$xChemotherapy.
676   $a615.5/8
700   $aVins?ova?$b Jarmila$01711024
701   $aKra?tky?$b Martin$f1960-$01711025
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910824260303321
996   $aDevelopment of new MDR-tuberculosis drugs$94102055
997   $aUNINA